Enviomycin
Also known as: Enviomycin sulfate, Tuberactinomycin N, Viomycin N
Source Enviomycin at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Enviomycin (tuberactinomycin N) is a cyclic peptide antibiotic of the tuberactinomycin family, closely related to viomycin. It is used as a second-line antitubercular agent, particularly for multidrug-resistant tuberculosis (MDR-TB). It is administered parenterally and shares cross-resistance with capreomycin and viomycin.
Mechanism of Action
Inhibits bacterial protein synthesis by binding to the 16S rRNA of the 30S ribosomal subunit, interfering with translocation and decoding; also disrupts cell membrane integrity in mycobacteria.
Routes of Administration
Goals & Uses
- Treatment of multidrug-resistant tuberculosis (MDR-TB)Infectious DiseaseModerate
- Treatment of drug-susceptible tuberculosisAntimicrobial / AntitubercularLow
Contraindications
- Pre-existing hearing loss or vestibular dysfunctionAuditory/VestibularModerate
- Hypersensitivity to enviomycin or tuberactinomycinsAllergicHigh
- Severe renal impairmentOrganHighKidney function concerns
Adverse Effects
- Vestibular toxicity (vertigo, ataxia)VestibularUncommon
- Electrolyte disturbances (hypokalemia, hypomagnesemia)MetabolicUncommon
- Injection site pain or indurationLocalCommon
- NephrotoxicityRenalCommon
- Ototoxicity (hearing loss, tinnitus)AuditoryCommon
Drug Interactions
- Aminoglycosides (e.g., streptomycin, amikacin)High
- Neuromuscular blocking agentsModerate
- CapreomycinHigh
- Loop diuretics (e.g., furosemide)High
Population Constraints
- PregnancyReproductive SafetyRelative
- Pediatric patientsAgeRelative
- Elderly patientsAgeRelative
- Patients with pre-existing renal diseaseOrgan DysfunctionRelative
Regulatory Status
- European UnionUnapprovedNot approved by the EMA; not commercially available in the European Union.
- United StatesUnapprovedNot approved by the FDA; not available commercially in the US.
- United KingdomUnapprovedNot approved by MHRA; not commercially available in the UK.
Approved in Japan for use against tuberculosis, including drug-resistant strains. Not approved by the US FDA or EMA as a standalone agent; considered an orphan/niche antibiotic in non-Japanese markets.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Enviomycin?
Enviomycin (tuberactinomycin N) is a cyclic peptide antibiotic of the tuberactinomycin family, closely related to viomycin. It is used as a second-line antitubercular agent, particularly for multidrug-resistant tuberculosis (MDR-TB). It is administered parenterally and shares cross-resistance with capreomycin and viomycin.
What is Enviomycin used for?
Enviomycin is educationally associated with: Treatment of multidrug-resistant tuberculosis (MDR-TB), Treatment of drug-susceptible tuberculosis. Educational only — not medical advice.
How is Enviomycin administered?
Recorded routes of administration: Intramuscular, Intravenous.
What are the potential side effects of Enviomycin?
Reported adverse effects include: Vestibular toxicity (vertigo, ataxia), Electrolyte disturbances (hypokalemia, hypomagnesemia), Injection site pain or induration, Nephrotoxicity, Ototoxicity (hearing loss, tinnitus). This list is not exhaustive — consult a qualified clinician.
Who should avoid Enviomycin?
Recorded contraindications: Pre-existing hearing loss or vestibular dysfunction, Hypersensitivity to enviomycin or tuberactinomycins, Severe renal impairment. Consult a qualified clinician before use.